Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
fomo momo hodl the biz is delivering
Avricore Health Corporate Update - Earnings Advisory 2022 and 2023 Objectives
https://money.tmx.com/en/quote/AVCR/news/7046287989064865/Avricore_Health_Corporate_Update_Earnings_Advisory_2022_and_2023_Objectives
https://www.proactiveinvestors.com/companies/news/1000418/avricore-health-sees-3q-revenue-soar-by-662-as-it-successfully-scales-its-healthtab-network-1000418.html
Avricore Health sees 3Q revenue soar by 662% as it successfully scales its HealthTab network
Break out, 450 installed Abbott's, major national pharma Shoppers Drug Mart
Thanks...not showing up anywhere else.
I see no news...
$AVCRF Tier Change- OTCQB to Pink Current
They changed the name b cause they don't sell pharmaceuticals anymore I guess? New name should be 'Avricore Worthless Paper'.
NUVPF: Effective Nov. 5,2018 VANC Pharmaceuticals Inc. will change to Avricore Health Inc.
http://otce.finra.org/DLSymbolNameChanges
This pathetic excuse for a company should have announced thst the day after they bought Corozon. But no. They chose to burn cash and bloat the shsre structure for 6 months instead. Maybe this can bounce back to $.20 so I can get out even. Probably not though!
VANC Contracts with Lampyon to Extend its Corozon Educational and Ecommerce Platform with Medical Cannabis Education and New Sales Capabilities
https://finance.yahoo.com/news/philippe-ugnat-llb-joins-vanc-003239638.html
Yup. These guys give the TSX.V a bad name. I can't wait to be finished scaling out of this garbage company. Sold 20k today. Ready to dump another 20k again on each uptick til im out for good. Can't wait.
Exactly. Let us have our freedom without picking our pockets any more. Hope they enjoyed their mojitos on our dime.
This company has no regard for shareholders whatsoever. If you want to make money on this POS then you have to wait until they crush the stock down to the basement to fill a PP, then flip it as they pump it up to keep the PP holders from screaming bloody murder. These guys a re so slow to do anything, they waited 6 months to announce they are integrating cannabis into their point of care modules or whatever, it's sad. I can;t wait for this to spike up a little higher so I can get the heck out with the rest of my shares. Terrible management imho.
Finally some movement so I can take some off the table here, thank goodness.
Cannabis flying, VANC asleep at the wheel. What else is new? SMH
It is literally shocking how incompetent the mgmt of this company is that they cannot capitalize in this environment in Canada. PATHETIC VANC
Im down like $20k on this nuvPOS... SMH
Back to $.10 range, maybe one day mgmt will get their act together. These guys are just wasting time and shareholder money every day they don't update on their plans with EMH... Ridiculous!
There is no reason we should be down here sub $.20 given the partnership with EMH, hopefully now with legalization on deck in Canada these guys are ready to hit the gas. It shouldn't take much, just a few updates on the Emerald partnership and VANC should be pushing back up hard on this SS. Fingers crossed.
The time is past due for a gameplan here. I’ve held these shares at a loss long enough. Hopefully this will shed some light on some profitable developments. :)
Vanc Pharma hires Transcend for IR services
2018-08-23 16:42 ET - News Release
Mr. Bob Rai reports
Vanc Pharmaceuticals Inc. has entered into a consulting agreement with Transcend Capital Inc. to develop and implement an investor relations program for the company. Transcend, with offices in Vancouver, B.C., is a full-service investor relations firm that assists small and mid-cap public companies with market awareness campaigns, and helps these companies gain valued industry exposure through an extensive network of retail and institutional clients. Etienne Moshevich is the sole owner of Transcend.
Transcend will provide comprehensive investor relations services to the company for an initial period of 24 months for an aggregate fee of $150,000 plus applicable taxes. Transcend and its directors, officers and employees are shareholders of the company, collectively holding approximately 3.5 per cent of the issued and outstanding common shares of the company.
The investor relations consulting agreement is subject to the approval of the TSX Venture Exchange.
About Vanc Pharmaceuticals Inc.
Vanc Pharmaceuticals aims to become the partner of choice for forward-thinking pharmacies across Canada. With an established sales force, distribution network, and team of highly experienced professionals in pharmacy, point-of-care testing and health technology, Vanc is growing beyond generics to provide pharmacists with innovative, value-added products and services to expand their scope of practice and support their evolving role as front-line healthcare providers.
We seek Safe Harbor.
© 2018 Canjex Publishing Ltd. All rights reserved.
https://www.stockwatch.com/News/Item.aspx?bid=Z-C%3aVANC-2650215&symbol=VANC®ion=C
Emerald Health Therapeutics Inc.
Exchange: TSXV Exchange
$4.65 Aug 23, 2018, 4:00 PM EDT 0.35 (8.14%)Vol: 5,348,395
Boom another huge day for big bad EMH... Quiet little TSX VANC waiting for the signal from big bro EMH, tick tock NUVPF, hopefully soon we have timely and significant updates. Gltua here with VANC/NUVPF and EMH/EMHTF.
Another great day for NUVPF partner/holder EMHTF +15% today back over $3 USD... lets go VANC bring the updates on cannabis partnership with EMHTF let's go!
Finally some relief. EMHTF moving North and bringing little bro NUVPF with.
Blah.. Im getting sick of this POS, mgmt here is moving too damn slow!
Yes hopefully it will be quick, the drop has been on low volume and we have not heard anything about the partnership with EMH for the entire time it's been dropping... Any positive news on the partnership and this should snap back hard imo. Fingers crossed NUVPF
Can’t wait to hear something. Maybe in the next week or two? Let’s get things going.
PP closed, time to move back north hopefully they have some developments with EMH coming soon
Still holdin amigo lets go!
Agreed. Im adding down here, I think this has been forced down so they can do another PP here while VANC is still under the radar and SP is in the gutter. All it needs is some confirmarion of pharmacy cannabis distribution and NUVPF should be headed to $1 land while EMH heads toward $10. Jmho
Wish it weren't so. But I'm red here sooo, I kinda want to move up bro. Fact is, pps has been taken down over the last couple of months on relatively low volume. Any kind of distribution/sales news should take us back to .20+ imo. $NUVPF
NUVPF it is ridiculous how hard it is to get my buys executed here. I am forced to pay way above the ask if I want a fill. Smh
I was just looking at SEDAR and on July 11 VANC announced a private placement for $1M @ $0.15 per ubit CAD... Probably explains why the price has been depressed while they complete the PP. I wouldn't surprise me if EMH takes down a large chunk of the PP.
Emerald Health Therapeutics (Puresun Farms) just got its sales license...would not be surprised to hear some good news here soon. $NUVPF
NUVPF will have its day in the sun, Im sure.
That's very interesting, I was in ATTB* when it ran to $2 back in 2014, before it became bloated, (post #22 all time actually https://investorshub.advfn.com/boards/read_msg.aspx?message_id=95700527) so Im familiar with nrthrn vine. VANC has real promise, largely buttressed by its relatively unscathed SS. It would be a good acquisition target for EMH especially if Canada commits to pharmacy distribution of THC derivatives. Time will tell my friend. GL
Tick tock my friends. :) $NUVPF
Emh just bought out northern vine wonder if nuvpf is next that would be whole distribution system !
As much as I am disappointed by the performance here, I look around and see sector darlings (i.e. EMH) also getting beaten down, and so I see perhaps there is a silver lining to this and I may add another lot to my pile here in the next few weeks in this depressed price range. When EMH is back over $5 then VANC should also be dramatically higher at that time as well, perhaps testing new highs. I don't know what the time frame on that is, but maybe close to 2019. Whay do you think?
Yeah I think ur probably right there.
Looks like they owed a 6k from a old news release .. I think imho
Followers
|
9
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
308
|
Created
|
07/20/15
|
Type
|
Free
|
Moderators |
VANCOUVER, British Columbia, May 03, 2018 (GLOBE NEWSWIRE) -- VANC Pharmaceuticals Inc. (“VANC”) (TSXV:VANC) (OTCQB:NUVPF) Board of Directors provided guidance on future company direction and initiatives today.
“In 2017 VANC had begun to anticipate secular changes affecting the generic and community pharmacy industries,” stated Mr. Bob Rai, CEO of VANC. “These changes included the trend towards increased funded participation by pharmacists in healthcare treatment of Canadians as well as dramatically shrinking margins on generic drugs. Our recent strategic partnerships, acquisitions and key personnel changes are a direct reflection of our vision, with a clear focus on growing beyond generics to provide pharmacists with innovative, value-added products, services and information to support their evolving business models and expanding role as front-line healthcare providers,” concluded Mr. Rai.
Concurrent with VANC’s new focus, the company will be reducing its generic portfolio over the next several months. Emerging opportunities in new healthcare sectors and the diminished ability to profit from generic sales drove this strategic decision. The realignment will provide existing products and services with increased focus and resources. This will also drive the expansion of a portfolio of high-margin over the counter (OTC) and point of care (POC) testing products and services that offer unique value to pharmacists, their patients, and consumers.
VANC is expanding its portfolio with announcements of strategic partnerships with Emerald, acquisition of the Corozon Platform, and plans to increase deployment of and expand offerings associated with HealthTab.
The recently announced strategic partnership with Emerald enables VANC to compete in the emerging medical cannabis sector with a line of endocannabinoid enhancers and with the potential to distribute medical cannabis to pharmacies when that avenue of sales is legalized.
“With a renewed focus on high-margin OTC/BTC product development, in addition to our recently announced partnership with Emerald Health, we anticipate generating increased sales and profitability in this pillar of the business in 2018,” explained Mr. Rai. “This shift in focus has also allowed us to engage with sales brokers across Canada, providing greater coverage to our products.”
The Corozon Platform, acquired in April 2018, offers a variety of functionalities including e-learning, e-commerce and potentially promotional modules. These capabilities ideally position it to serve as an anchor for this pillar of the business, functioning as an educational tool and distribution channel for a number of VANC products, including those the company will distribute for Emerald.
Mr. Rai added: “We will be able to leverage the Platform to promote our latest offerings and educate pharmacists on how to use them effectively. It will serve to drive our relationships with pharmacists and will also be a powerful retention tool. Through Corozon, we can efficiently market new services and products directly to the pharmacist.”
HealthTab will form the core of VANC’s future expansion of its point of care pharmacy screening tests to empower pharmacists and improve patient health. HealthTab as it is today will provide pharmacists with a platform to integrate precise blood chemistry into billable medicine reviews for patients in a timely and convenient manner.
“Our HealthTab service is based on a unique technology initially developed to provide a lab quality yet simple test for astronauts on the International Space Station. VANC can now provide this service to the general population. It will change how patients manage their health. It will also benefit the community by serving as a simple screening tool to detect serious conditions such as kidney failure or high cholesterol,” said Mr. Rai.
HealthTab systems have already been launched with strategic community pharmacy pilot programs in BC and Ontario. Furthermore, commitments for additional deployments have been secured and are scheduled for launch in Q2 2018. Additional tests to complement those currently offered by the HealthTab framework are in development and will make it best in class in terms of scope and accessibility to patients.
“The Emerald investment and licensing and the HealthTab and Corozon Platform acquisitions represent significant first steps in repositioning VANC. Further steps are being taken to create the structure and branding that will drive the evolution of our business to a new level in 2018,” concluded Mr. Rai.
About VANC Pharmaceuticals Inc.
VANC Pharmaceuticals aims to become the partner of choice for forward-thinking pharmacies across Canada. With an established sales force, distribution network, and team of highly experienced professionals in pharmacy, point-of-care testing, and health technology, VANC is growing beyond generics to provide pharmacists with innovative, value-added products and services to expand their scope of practice and support their evolving role as front-line healthcare providers.
For more information, please contact Bob Rai at 604-247-2639 or by email at info@vancpharm.com.
Cautionary Note Regarding Forward-looking Statements: Information in this press release that involves VANC’s expectations, plans, intentions or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. VANC generally uses words such as “outlook,” “will,” “could,” “would,” “might,” “remains,” “to be,” “plans,” “believes,” “may,” “expects,” “intends,” “anticipates,” “estimate,” “future,” “plan,” “positioned,” “potential,” “project,” “remain,” “scheduled,” “set to,” “subject to,” “upcoming,” and similar expressions to help identify forward-looking statements. The forward-looking statements in this release are based upon information available to VANC as of the date of this release, and VANC assumes no obligation to update any such forward-looking statements. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of VANC and are subject to risks, uncertainties and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contact:
Bob Rai, Director, and CEO
604-247-2639
info@vancpharm.com
www.vancpharm.com
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |